Stroke: Working Toward a Prioritized World Agenda

The aim of the Synergium was to devise and prioritize new ways of accelerating progress in reducing the risks, effects, and consequences of stroke

Patient and Disease Characteristics for Patients Receiving Multiple Doses.

<p>BSA = body surface area; IL-20 = interleukin 20; PASI = Psoriasis Area and Severity Index score.</p><p>Patient and Disease Characteristics for Patients Receiving Multiple Doses.</p

Mean PASI total score by visit.

<p>Mean PASI total score by visit following (A) single dosing or (B) multiple dosing in the dose-escalation phase and (C) multiple dosing in the expansion phase. PASI = Psoriasis Area and Severity Index.</p

Summary of Pharmacokinetic Parameters After Dosing With Anti‒IL-20.

<p>AUC = area under the curve; C_max = maximum concentration; CV = coefficient of variation; IL-20 = interleukin 20; t_½ = half-life.</p><p>Summary of Pharmacokinetic Parameters After Dosing With Anti‒IL-20.</p

Study design.

<p>The first dose in the multiple-dose dose-escalation phase was administered after the third dose level of the single-dose dose-escalation phase (0.2 mg/kg) was evaluated by a study safety group; thereafter, the single- and multiple-dose dose-escalation phases were performed in parallel.</p

Consort flow diagram.

<p>Patient disposition in (A) the single-dose and multiple-dose dose-escalation phases and (B) the multiple-dose expansion phase. Represents the safety analysis set. AE = adverse event.</p